Comment
doi: 10.2146/ajhp110228.
Should the FDA approval process for weight-loss drugs be modified?
Affiliations
- PMID: 22011989
- DOI: 10.2146/ajhp110228
Item in Clipboard
Comment
Should the FDA approval process for weight-loss drugs be modified?
Am J Health Syst Pharm.
.
No abstract available
Comment on
-
Lorcaserin: an investigational serotonin 2C agonist for weight loss.Am J Health Syst Pharm. 2011 Nov 1;68(21):2029-37. doi: 10.2146/ajhp100638. Am J Health Syst Pharm. 2011. PMID: 22011982 Review.
Similar articles
-
Lorcaserin for weight loss: insights into US Food and Drug Administration approval.J Acad Nutr Diet. 2013 Jan;113(1):25-30. doi: 10.1016/j.jand.2012.08.028. J Acad Nutr Diet. 2013. PMID: 23260720 No abstract available.
-
The FDA's assessment of two drugs for chronic weight management.N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10. N Engl J Med. 2012. PMID: 23050510 No abstract available.
-
Drug management of obesity--efficacy versus safety.N Engl J Med. 2010 Jul 15;363(3):288-90. doi: 10.1056/NEJMe1004076. N Engl J Med. 2010. PMID: 20647205 No abstract available.
-
Pharmacotherapy for obesity: What you need to know.Cleve Clin J Med. 2017 Dec;84(12):951-958. doi: 10.3949/ccjm.84a.16094. Cleve Clin J Med. 2017. PMID: 29244650 Review.
-
Overview of new antiobesity drugs.Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6. Expert Opin Pharmacother. 2014. PMID: 25100293 Review.
Cited by
-
Anti-Obesity Agents and the US Food and Drug Administration.Curr Obes Rep. 2014 Sep;3(3):361-7. doi: 10.1007/s13679-014-0115-x. Curr Obes Rep. 2014. PMID: 26626768
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
